Key statistics
As of last trade, Immunoprecise Antibodies Ltd (IPA:NMQ) traded at 0.4724, 34.86% above the 52 week low of 0.3503 set on Nov 06, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.530 |
---|---|
High | 0.530 |
Low | 0.404 |
Bid | 0.47 |
Offer | 0.4748 |
Previous close | 0.47 |
Average volume | 310.96k |
---|---|
Shares outstanding | 28.83m |
Free float | 25.36m |
P/E (TTM) | -- |
Market cap | 13.55m USD |
EPS (TTM) | -0.7482 USD |
Data delayed at least 15 minutes, as of Nov 13 2024 16:43 GMT.
More ▼
- $20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer Therapies
- ImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics Innovation
- ImmunoPrecise Advances Anti-Aging Research with Mayo Clinic Study, Poised to Tap into $81 Billion Market with AI Technology
- ImmunoPrecise Antibodies to Participate at the AI Driven Drug Discovery Summit USA 2024
- ImmunoPrecise Antibodies Celebrates Nobel Prize in Chemistry, Advances in AI-Powered Protein Design
- ImmunoPrecise Subsidiary Signs Material Transfer Agreement with Biotheus
- ImmunoPrecise Antibodies Advances Therapeutic Innovation with Groundbreaking Rabbit Antibody Developments
- ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025
- IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 on September 16, 2024
- ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York
More ▼